XM은(는) 미국 국적의 시민에게 서비스를 제공하지 않습니다.

Tate & Lyle’s sour M&A may have nicer aftertaste



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>CORRECTED-BREAKINGVIEWS-Tate & Lyle’s sour M&A may have nicer aftertaste</title></head><body>

Corrects first paragraph to state that Tate & Lyle is a former rather than current sugar producer. The author is a Reuters Breakingviews columnist. The opinions expressed are her own.

By Aimee Donnellan

LONDON, June 20 (Reuters Breakingviews) -Tate & Lyle’s TATE.L latest spot of M&A may be more appetising than it looks. On Thursday, the $3.2 billion former cane sugar producer splurged $1.8 billion on ingredient business CP Kelco. A 7% fall in the buyer’s shares suggests investors may be focusing on sour returns. But the deal’s strategic logic may yet provide a pleasant aftertaste.

Tate & Lyle CEO Nick Hampton is coming to the end of his transformation plan. Hampton, who took over in 2018, has been shifting the business away from its commodity past and focusing it more on “clean label” ingredients that are not considered artificial additives. Last month, he also flogged his remaining stake in plant-based ingredient maker Primient, raising $1.5 billion in the process to bolster the company’s balance sheet and allow it to do a deal like CP Kelco.

Buying an ingredients business with better exposure to large growth markets like China and Latin America makes sense. And buying CP Kelco’s pectin-based ingredients can help offset the key flaw with clean label ingredients – they don’t taste as nice. Low-fat yogurts, for example, often have an unappetising consistency due to the loss of fat and sugar.

Some of the reasons for Thursday’s share price slide aren’t deal-related: Tate & Lyle paid a dividend on Thursday, and it is also part-paying for CP Kelco by giving owner J.M. Huber a 16% share in its business by issuing equity, which dilutes current investors. Yet the deal’s returns still look underwhelming.

Last year, CP Kelco’s revenue dropped 3% and its adjusted operating profit fell 26% to $62 million. Add $50 million of expected cost synergies and tax them at 22%, and the $1.8 billion outlay only yields a 5% return. That’s a long way from Tate & Lyle’s 9% cost of capital, a rough proxy for the target’s.

Yet Hampton can argue CP Kelco is in a temporary slump. Inflationary pressures are easing, which may encourage consumers to spend more. Supply chain disruptions also hit revenue and profits. Imagine sales grow at around 9% next year, the level achieved in 2021, and CP Kelco musters the 23% EBITDA margin it made that year. Lop off $69 million of depreciation and amortisation and add the synergies, and next year’s return would be near 8%. Fold in the strategic logic, and Tate & Lyle’s latest gambit has at least a path to passing the taste test.

Follow @aimeedonnellan on X


CONTEXT NEWS

Britain’s $3.2 billion food ingredients maker Tate & Lyle said on June 20 it had entered into an agreement to buy CP Kelco, a leading provider of pectin and speciality gums, for $1.8 billion from privately held U.S. group J.M. Huber Corporation.

Tate, one of the world’s biggest producers of sweeteners, expects to generate $50 million of cost synergies in the second full financial year following completion of the deal. It also expects to generate revenue synergies of up to 10% of CP Kelco’s sales over the medium term.

Tate will finance the deal with $1.15 billion of cash and $645 million of new shares issued to J.M. Huber.

Tate & Lyle shares were down 7% at 630 pence as of 0952 GMT on June 20.


Graphic: Tate & Lyle’s performance under its current CEO https://reut.rs/3zdsD7d


Editing by George Hay and Oliver Taslic

</body></html>

면책조항: XM Group 회사는 체결 전용 서비스와 온라인 거래 플랫폼에 대한 접근을 제공하여, 개인이 웹사이트에서 또는 웹사이트를 통해 이용 가능한 콘텐츠를 보거나 사용할 수 있도록 허용합니다. 이에 대해 변경하거나 확장할 의도는 없습니다. 이러한 접근 및 사용에는 다음 사항이 항상 적용됩니다: (i) 이용 약관, (ii) 위험 경고, (iii) 완전 면책조항. 따라서, 이러한 콘텐츠는 일반적인 정보에 불과합니다. 특히, 온라인 거래 플랫폼의 콘텐츠는 금융 시장에서의 거래에 대한 권유나 제안이 아닙니다. 금융 시장에서의 거래는 자본에 상당한 위험을 수반합니다.

온라인 거래 플랫폼에 공개된 모든 자료는 교육/정보 목적으로만 제공되며, 금융, 투자세 또는 거래 조언 및 권고, 거래 가격 기록, 금융 상품 또는 원치 않는 금융 프로모션의 거래 제안 또는 권유를 포함하지 않으며, 포함해서도 안됩니다.

이 웹사이트에 포함된 모든 의견, 뉴스, 리서치, 분석, 가격, 기타 정보 또는 제3자 사이트에 대한 링크와 같이 XM이 준비하는 콘텐츠 뿐만 아니라, 제3자 콘텐츠는 일반 시장 논평으로서 "현재" 기준으로 제공되며, 투자 조언으로 여겨지지 않습니다. 모든 콘텐츠가 투자 리서치로 해석되는 경우, 투자 리서치의 독립성을 촉진하기 위해 고안된 법적 요건에 따라 콘텐츠가 의도되지 않았으며, 준비되지 않았다는 점을 인지하고 동의해야 합니다. 따라서, 관련 법률 및 규정에 따른 마케팅 커뮤니케이션이라고 간주됩니다. 여기에서 접근할 수 있는 앞서 언급한 정보에 대한 비독립 투자 리서치 및 위험 경고 알림을 읽고, 이해하시기 바랍니다.

리스크 경고: 고객님의 자본이 위험에 노출 될 수 있습니다. 레버리지 상품은 모든 분들에게 적합하지 않을수 있습니다. 당사의 리스크 공시를 참고하시기 바랍니다.